Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China

Abstract

Chronic myeloid leukemia (CML) is a rare disease among children. A retrospective study was conducted from November 2002 to March 2019 at a single institution in China. A total of 36 pediatric CML patients (25 male and 11 female) were enrolled. Median follow-up time was 51\xa0months (range 8–144), and 5-year overall survival and event-free survival were 95.5\u2009±\u20094.4% and 88.9\u2009±\u20096.0%, respectively. Among the 25 patients whose response to imatinib mesylate (IM) was regularly monitored, 92.0% achieved complete hematologic response at 3\xa0months, 80.0% achieved complete cytogenetic response at 12\xa0months, and 64.0% achieved major molecular response at 18\xa0months after IM therapy. A higher WBC count at diagnosis was associated with failure to achieve early molecular response (EMR). Height standard deviation score after long-term treatment was significantly and positively correlated with age at diagnosis and at the start of IM therapy. Overall, IM therapy was effective in treating pediatric CML, and WBC count at diagnosis might be an ideal predictor of EMR. Moreover, retardation of height and weight growth due to IM tended to affect patients younger than 9\xa0years old at diagnosis, and longitudinal growth might normalize further into treatment.